Shares of Dermira (NASDAQ:DERM) dropped 6.5% on Monday . The stock traded as low as $9.58 and last traded at $9.80. Approximately 1,301,372 shares changed hands during mid-day trading, an increase of 4% from the average daily volume of 1,248,641 shares. The stock had previously closed at $10.48.
DERM has been the subject of several recent research reports. Cantor Fitzgerald set a $20.00 price objective on Dermira and gave the company a “buy” rating in a research report on Monday, April 9th. Cowen set a $25.00 price objective on Dermira and gave the company a “buy” rating in a research report on Monday, March 5th. Needham & Company LLC lowered their price objective on Dermira from $43.00 to $19.00 and set a “buy” rating for the company in a research report on Tuesday, March 6th. BidaskClub upgraded Dermira from a “hold” rating to a “buy” rating in a research report on Friday, May 4th. Finally, Zacks Investment Research upgraded Dermira from a “hold” rating to a “buy” rating and set a $11.00 price objective for the company in a research report on Tuesday, May 22nd. Three investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $29.63.
The company has a debt-to-equity ratio of 2.19, a current ratio of 5.17 and a quick ratio of 5.17. The firm has a market cap of $438.57 million, a P/E ratio of -2.23 and a beta of 1.46.
Dermira (NASDAQ:DERM) last announced its earnings results on Thursday, May 3rd. The biopharmaceutical company reported ($1.39) EPS for the quarter, missing analysts’ consensus estimates of ($1.30) by ($0.09). The business had revenue of $0.30 million for the quarter. Dermira had a negative net margin of 8,823.69% and a negative return on equity of 95.84%. equities analysts forecast that Dermira will post -5.17 earnings per share for the current fiscal year.
In other Dermira news, CEO Thomas G. Wiggans bought 12,150 shares of the firm’s stock in a transaction that occurred on Monday, June 25th. The stock was bought at an average price of $9.84 per share, for a total transaction of $119,556.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 14.80% of the stock is owned by corporate insiders.
Institutional investors have recently made changes to their positions in the stock. AXA raised its holdings in shares of Dermira by 1.0% during the fourth quarter. AXA now owns 303,474 shares of the biopharmaceutical company’s stock valued at $8,440,000 after acquiring an additional 3,141 shares in the last quarter. Schwab Charles Investment Management Inc. grew its stake in Dermira by 20.2% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 180,235 shares of the biopharmaceutical company’s stock worth $5,013,000 after purchasing an additional 30,244 shares during the period. Candriam Luxembourg S.C.A. purchased a new stake in Dermira in the first quarter worth $1,598,000. MetLife Investment Advisors LLC purchased a new stake in Dermira in the fourth quarter worth $504,000. Finally, Bailard Inc. purchased a new stake in Dermira in the first quarter worth $775,000. Institutional investors own 87.35% of the company’s stock.
Dermira, Inc, a biopharmaceutical company, identifies, develops, and commercializes therapies to treat dermatologic diseases. The company's product candidates include Glycopyrronium tosylate, a novel form of an anticholinergic agent that has completed Phase III clinical trial for the treatment of primary axillary hyperhidrosis; Olumacostat glasaretil, a novel small molecule designed to target sebum production, which is in Phase III clinical trial for the treatment of acne vulgaris; and lebrikizumab, a novel humanized monoclonal antibody targeting interleukin 13 that is in Phase 2b development for the treatment of moderate-to-severe atopic dermatitis.
Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.